{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:06:03Z","timestamp":1762520763637},"reference-count":10,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":84,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,9,27]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>It may be possible to achieve more effective management of Crohn\u2019s Disease by introducing a flexible dosage regimen sensitive to patients\u2019 needs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>Comparison of the efficacy and tolerability of a fixed vs. flexible budesonide controlled ileal release treatment regimen for the prevention and management of relapse in Crohn\u2019s disease patients. Budesonide controlled ileal release is an oral formulation which delivers drug directly to disease sites in the ileum and ascending colon, by preventing more proximal release and absorption.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A randomized, double\u2010blind comparison of a fixed dose of budesonide controlled ileal release (6\u2003mg o.m.) and a flexible dose of budesonide controlled ileal release (3, 6 or 9\u2003mg o.m.) for 12\u2003months, in 143 patients in remission from ileal or ileo\u2013caecal Crohn\u2019s Disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Very low rates of clinical relapse in Crohn\u2019s disease were achieved with budesonide controlled ileal release 6\u2003mg o.m. There was no significant difference between the treatment groups with respect to the survival estimate of percentage of treatment failures (flexible group 15%, fixed group 19%; <jats:italic>P<\/jats:italic>=0.61). The average consumed dose of budesonide was comparable in both groups (5.8\u2003mg flexible, 6.0\u2003mg fixed). Similar proportions of patients reported adverse events (flexible 100%, fixed 97%). There were 33 serious adverse events (flexible 19, fixed 14) and 13 withdrawals due to significant adverse events (flexible 9, fixed 4).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Maintenance treatment with budesonide controlled ileal release 6\u2003mg o.m. is well\u2010tolerated and is associated with low rates of clinical relapse in stable Crohn\u2019s disease over 12\u2003months. Flexible dosing remains an option for individual patients, but this study has shown no advantage over a standard fixed dosing regimen.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.01055.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:45:08Z","timestamp":1047354308000},"page":"1331-1341","source":"Crossref","is-referenced-by-count":21,"title":["Maintenance of Crohn\u2019s disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules"],"prefix":"10.1111","volume":"15","author":[{"given":"J. R. B.","family":"Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Giaffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Travis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. C.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"THE FREEDOM INVESTIGATOR GROUP","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/0016-5085(79)90386-X","article-title":"National Cooperative Crohn\u2019s Disease Study: adverse reactions to study drugs","volume":"77","author":"Singleton JW","year":"1979","journal-title":"Gastroenterology"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199402000-00007"},{"key":"e_1_2_6_4_2","first-page":"A722","article-title":"Budesonide CR for maintenance of remission in ileocecal Crohn\u2019s Disease. A European multi centre placebo controlled trial for twelve months","volume":"106","author":"Lofberg R","year":"1993","journal-title":"Gastroenterology"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(76)80163-1"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(79)90385-8"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199504000-00008"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00438.x"},{"key":"e_1_2_6_9_2","first-page":"A970","article-title":"for the International BUD Maintenance Investigators. Budesonide controlled ileal release prolongs remission in Crohn\u2019s disease (CD): a pooled analysis","volume":"112","author":"Feagan B","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409293311304"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.2.209"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01055.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01055.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.01055.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T15:25:55Z","timestamp":1695828355000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.01055.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9,27]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2001,9,27]]}},"alternative-id":["10.1046\/j.1365-2036.2001.01055.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.01055.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"type":"print","value":"0269-2813"},{"type":"electronic","value":"1365-2036"}],"subject":[],"published":{"date-parts":[[2001,9,27]]}}}